Trial · NCT04598477
Outcomes11
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of Treatment-Emergent Adverse Events (TEAE), Adverse Events of Special Interest (AESI), and Serious Adverse Events (SAE) | Up to 60 weeks | Safety set | number of events x 100/PYFU | NUMBER |
| SECONDARY | Proportion of Participants With Pemphigus Vulgaris (PV) and Pemphigus Foliaceus (PF) Who Achieve CRmin | Up to 60 weeks | Safety set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Proportion of Participants With Pemphigus Vulgaris (PV) Who Achieve CRmin | Up to 60 weeks | Safety set - Participants with PV | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Time to DC in Participants With PV and PF | Up to 52 weeks | Safety set - Participants with status DC at the roll-over visit were not included in the analysis. | days | MEDIAN |
| SECONDARY | Time to CR in Participants With PV and PF | Up to 52 weeks | Safety set - Participants with status CR at the roll-over visit were not included in this analysis. | Days | MEDIAN |
| SECONDARY | Time to CRmin in Participants With PV and PF | Up to 52 weeks | Safety set - Participants with status CRmin at the roll-over visit were not included in this analysis. | days | MEDIAN |
| SECONDARY | Time to CRoff in Participants With PV and PF | Up to 52 weeks | Safety set - Participants with status CRoff at the roll-over visit were not included in this analysis. | days | MEDIAN |
| SECONDARY | Time to Flare After CRmin in Participants With PV and PF | Up to 52 weeks | Safety set - Only participants who achieved CRmin were considered for the analysis. | days | MEDIAN |
| SECONDARY | Rate of Treatment Failure in Participants With PV and PF | Up to 52 weeks | Safety set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Flares in Participants With PV and PF | Up to 60 weeks | Roll-over set - Only participants who achieved DC were considered for the analysis. | Flares | MEAN |
| SECONDARY | Normalized Cumulative Prednisone Dose in Participants With PV and PF | Up to 60 weeks | Roll-over set - For participants that do not achieve CRmin (or CRoff), NCPD until CRmin (or CRoff) is not calculated | mg/kg/day | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04598477/outcomes